A revolutionary test for the detection of mutations associated with colorectal cancer has been launched by Randox. This early, patient-friendly test allows the analysis of DNA in stool samples without the need for dietary or medication changes.
However, it is thought that chromosomal instability accounts for 85% of sporadic colorectal cancers. Therefore, the ability to screen for point mutations from this pathway using the Randox test in a patient presenting with a positive faecal occult blood test would be a valuable aid to the screening process by providing a highly specific test that may also benefit from increased patient compliance.
The DNA array from Randox allows the detection of 28 mutations associated with the chromosomal instability pathway. It is hoped that this revolutionary test will increase early detection of cancer and precancerous lesions and thus reduce the level of mortality associated with colorectal cancer.
Randox Laboratories www.randox.com